Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Oncology·MeSH: Carcinoma
3 drugs in development·1 company·1 clinical trial
Drug Pipeline by Phase
Compare drugs
Frequently asked questions
How many drugs are in development for Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations?
BioSniper tracks 3 drugs in development for Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations across 1 company.
How many clinical trials target Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations?
There are 1 clinical trial targeting Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations tracked by BioSniper.
Analyze CG Oncology, Inc.'s Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations pipeline with AI
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start AI Analysis